INTRODUCTION 1
Trauma remains one of the world's leading causes of death [1] with upwards of 2 million 2 people dying from trauma hemorrhage each year [1, 2] . Advances in our understanding of 3 trauma-induced coagulopathy (TIC) and new approaches to resuscitation have led to large 4 improvements in outcomes [3] . However even in the best centers, one in four trauma patients 5 with severe bleeding die, and overall mortality may approach 50% [4] . Current resuscitation 6 often manages coagulopathy empirically, is non-specific and does not correct a pre-existing 7 coagulopathy [5, 6] . A targeted, precision medicine approach to the treatment of TIC may lead 8 to improved outcomes while reducing overall requirements for red cells and component 9 therapies. 10 11 TIC has multiple phenotypes and individual patients may present with different forms of 12 coagulopathy at different times in their clinical course [7, 8] . Contemporary resuscitation of 13 bleeding trauma patients delivers volume resuscitation through an empiric, balanced 14 transfusion of red blood cells, plasma and platelets in proportions approximating that of 15 whole blood [9] . While this approach reduces the development of dilutional coagulopathy, it 16 does not treat any underlying coagulopathy and does not fully support hemostasis in patients 17 who require large volumes of transfusion [5, 6] . The targeted correction of underlying 18 coagulopathy using conventional coagulation tests (CCTs) is attractive in principle and 19 supported by small trials [10, 11] . However, the logistics of providing laboratory results in a 20 suitable timeframe are challenging [11, 12] . This has led to the suggestion of a hybrid 21 approach, starting with empiric therapy and switching to an individualized, precision 22 approach as soon as coagulation assessments are available [13] [14] [15] . This approach ideally 23 requires rapidly available point of care assessments of coagulopathy and has resulted in 24 renewed interest in viscoelastic hemostatic assays (VHAs) to diagnose the underlying 25 hemostatic deficiencies and to guide coagulation support. However, there is currently 1 insufficient data to support the use of VHAs in trauma hemorrhage [16] [17] [18] [19] [20] . While a number 2 of small studies shows VHA results can predict transfusion requirements or guide therapy, 3 there is minimal evidence for parameters to guide the administration of coagulation 4 therapeutics during active trauma hemorrhage [21-23]. 5
6
The overall objective of this study was to develop pragmatic data-driven algorithms for the 7 VHAs in the management of TIC during trauma hemorrhage. Our first aim was to determine, 8 for both thromboelastometry (ROTEM®) and thromboelastography (TEG®), parameters and 9 thresholds with high detection rate for TIC. We then aimed to determine the optimum 10 parameters to guide therapyspecifically thresholds to guide the treatment of 11 hypofibrinogenemia, thrombocytopenia, coagulation factor deficiency and hyperfibrinolysis. 12
Finally, we wished to synthesize these findings into pragmatic algorithms for clinical practice. 13
14

METHODS 15
Study design 16
This study was part of the TACTIC (Targeted Action for Curing Trauma Induced 17
Coagulopathy) program [24] of the International Trauma Research Network (INTRN) [25]. 18
The prospective multinational observational study ACIT (Activation of Coagulation and 19 Inflammation in Trauma) was the research platform for the study. Patients were recruited 20 prospectively at six major trauma centers in five different countries -the UK, Denmark, 21 Germany, the Netherlands and Norway. 22
Participants 23
Adult trauma patients who met the local criteria for full trauma team activation were eligible 24 for inclusion. Patients who received more than 2000 mL of fluids before arrival in the 25 emergency department (ED) or who arrived more than 2 hours from time of injury were 1 excluded, as were patients who were pregnant, had known liver failure, pre-existing bleeding 2 disorders or were taking oral anticoagulants other than aspirin. Patients who had received 3 blood products or Tranexamic Acid (TXA) before admission were not excluded. Initial 4 consent was provided by a physician independent of the study. Written informed consent was 5 obtained as soon as possible from the patients or their next of kin. The study was approved by 6 local ethical authorities and performed in accordance with local ethical regulations and the 7 Declaration of Helsinki. 8
Data collection 9
Patient demographics, time and mechanism of injury, pre-hospital fluid administration, vital 10 signs on admission, total amount of fluids and blood products administered within the first 12 11 hours, and CCTs on admission were collected prospectively. Injury severity was scored when 12 relevant information was available. TEG and ROTEM values were recorded electronically 13 and later transferred manually to the case report form (CRF). 14
Sampling techniques and measurements 15
ACIT first began recruiting patients in 2008 with ROTEM, and TEG analyses were added in 16 parallel from 2013. Blood samples were collected within 20 minutes of arrival in the ED. 17
Samples for TEG, ROTEM and CCTs were collected in citrated tubes. Samples for blood gas 18 analyses were collected in heparinized syringes in accordance with local routines. TEG and 19
ROTEM were performed within one hour, at 37°C by dedicated study personnel using the 20 TEG 5000® Thrombelastograph Hemostasis Analyzer (Haemonetics Corp., Braintree, MA, 21 US) and the ROTEM Delta® (TEM international GmbH, Munich, Germany). The 22 methodology and the parameters of TEG and ROTEM have been described previously 23 [26, 27] . 24 6
ROTEM, TEG and CCT analyses 1
The ROTEM assays used in this study were the EXTEM and FIBTEM, both activated by 2 tissue factor derived from rabbit brain, with cytochalasin D added to the FIBTEM sample for 3 platelet inhibition [27] . TEG assays were standard TEG, where the sample is activated by 4
Kaolin, Rapid TEG (rTEG) where the sample is activated by both Kaolin and tissue factor, 5
and Functional Fibrinogen TEG (FF TEG) where lyophilized tissue factor with a platelet 6
inhibitor Abciximab (a glycoprotein IIb/IIIa-inhibitor) is added for platelet inhibition to 7 isolate the fibrin component of the clot [27] . The CCTs were Prothrombin Time (PT), 8 fibrinogen concentration and platelet count (PLT). PT was converted to international 9 normalized ratio (INR) in accordance with the specific reagents and device characteristics in 10 the respective laboratories. Fibrinogen was measured by the Clauss method [28]. 11
Definitions 12
We defined the presence of TIC as INR > 1.2 [12]; hypofibrinogenemia was defined as 13 fibrinogen concentration < 2.0 g/L [9]; and thrombocytopenia as a platelet count below 100 x 14 10 9 /L [9,19]. In the absence of an accepted laboratory definition of hyperfibrinolysis in 15 trauma patients we aimed to determine threshold values for treatment through their 16 relationship with mortality and transfusion requirements. 17
Statistical analyses 18
Multiple imputations were performed on all TEG and ROTEM data, to deal with the missing 19 data. Predictive mean matching was performed and 10 imputation sets were constructed. The 20 imputations were tested using graphical density plots where the imputed data was plotted 21 separately from the original data and convergence was checked. The outcomes from the 22 analyses were pooled using Rubin's rule [29] . Statistical analyses were also performed with 23 non-imputed data, to confirm that multiple imputations had not introduced unacceptable bias. 24 and platelet transfusions given alongside red blood cell transfusions as the basis of their major 15 hemorrhage protocol [3, 19, 30] . All centers also empirically give tranexamic acid to all 16 patients activating the major hemorrhage protocol [31, 32] . This concept of personalized 17 hemostasis control augmenting baseline empiric therapy has been previously described as the 18 'Copenhagen Concept' [13] [14] [15] . 19 20 Algorithms were based on the principles that they should be able to guide hemostatic therapy, 21 namely fibrinogen replacement, platelet transfusions, plasma procoagulant supplementation 22 and antifibrinolytic therapy. Algorithms were also to be as pragmatic and easy to follow as 23 possible, using parameters that were not only strongly associated with underlying 24 coagulopathy states, but also had face validity to clinicians. The key outputs of this study are 25 the trigger thresholds for administration of coagulation therapies. We selected the earliest 26 available parameter that provided the required information and threshold levels that were at 1 least 70% sensitive despite potentially low specificity, as the interventions are known to carry 2 generally acceptable risk in a life-threatening setting. Threshold values were also selected to 3 be easier to recall if small changes (e.g. rounding up or down) would not significantly alter 4 the performance of individual parameters. For the therapies and doses associated with these 5 thresholds we chose best practice levels from current guidelines and evidence. AUCs and 95% CI). As expected, FIBTEM maximum clot firmness (MCF) also performed 19 well with an AUC of 0.78 (Figure 1 ) (see Table, 
Supplemental Digital Content 1: Detection of 20
Hypofibrinogenemia; AUCs and 95% CI). A FIBTEM CA5 threshold of 10mm had a 21 sensitivity of 70%, specificity of 76% and NPV of 88% for the detection of 22 hypofibrinogenemia (Table 2) . 23
For TEG the rTEG MA was the best performing variable with an AUC of 0.76 (Figure 1 ) (see 24 Figure 1 ) (see Table,  26 Supplemental Digital Content 1: Detection of Hypofibrinogenemia; AUCs and 95% CI). An 1 FF-TEG MA of 19 mm had a sensitivity of 70% and specificity of 59% for the detection of 2 hypofibrinogenemia, with an NPV of 89% (Table 2) a sensitivity of 74% with a specificity of 63% and a NPV of 99% (Table 3) . 12
For TEG the subtracting amplitude of FF TEG MA from the rTEG MA had an AUC of 0.54 13 (See Table, sensitivity of 65% with a specificity of 32% and NPV of 98% (Table 3) . 17
18
Detection of Hyperfibrinolysis 19
To identify thresholds for the detection of hyperfibrinolysis we examined the relationship 20 between viscoelastic lysis parameters and clinical outcomes. For ROTEM maximum lysis 21 (ML) there was a step-change in mortality in patients with a ML above 20% (ML %: ≤ 20% 22 vs > 20% -9.5% vs 50.0%, p < 0.001). At 30 minutes, the ROTEM Lysis Index (LI30) 23 parameter showed a similar mortality outcome threshold at 85% (LI30: < 85% vs ≥ 85% -24 76.2% vs 10.8%, p < 0.001). Only 3.5% of those with an LI30 above 85 % subsequently 25 developed an ML > 20%, of which 4 patients died (10.5% mortality -not significantly 1 different from LI30 ≥ 85% or ML < 20% groups). Mean 24-hour packed red blood cell 2 (PRBC) requirements also increased markedly at LI30 levels below 85% (LI30: < 85% vs ≥ 3 85% -14 vs 7 units, p < 0.001). 4
For TEG detection of hyperfibrinolysis, there was an increase in mortality at rTEG clot lysis 5 at 30 minutes (LY30) values above 10% (LY30: ≤ 10% vs > 10% -8.8% vs 60.0%, p < 6 0.001). There was an associated increase in PRBC requirements at this threshold: (LY30: ≤ 7 10% vs >10% -2 vs 10 units, p < 0.001). Based on the analyses above we constructed management algorithms for ROTEM, TEG and 5 CCTs (Fig 3a, b and c respectively) to be used in addition to baseline damage control 6 resuscitation (empiric high-dose plasma and platelets and baseline administration of 7 tranexamic acid). 8
ROTEM 10
Given the principles of timely availability, adequate performance and pragmatic triggers, we 11 defined a FIBTEM CA5 threshold of 10 mm for the dosing of additional fibrinogen (Table 2) . 12
For administering additional platelets transfusions, we used the EXTEM CA5 -FIBTEM 13 CA5 threshold of < 30 mm. To identify those patients who may require additional plasma 14 despite sufficient replacement of fibrinogen and platelets we selected a standard EXTEM CT 15 value of > 80 seconds in the presence of a non-coagulopathic EXTEM CA5 (> 40 mm). 16
Additional TXA would be administered when EXTEM LI30 < 85%. 17
TEG 19
We constructed a TEG algorithm using the same principles. We selected a FF TEG < 20 mm 20 as a threshold value for additional fibrinogen (Table 2) . For other parameters, rTEG 21 parameters were used rather than Kaolin TEG for their timeliness [33], given there was no 22 significant loss of sensitivity or specificity across these tests. We chose a rTEG -FF TEG 23 MA below 45mm as a threshold for giving additional platelet transfusions (Table 3) . For 24 additional plasma, we again used a standard rTEG ACT > 120 seconds' threshold provided 25 there was no indication for fibrinogen or platelets (i.e. rapid TEG MA > 65 mm (Table 4 
)). A 1
Rapid TEG LY30 > 10% was used as a threshold value for additional TXA. We have defined accurate, rapidly available parameters that identify the key coagulation 12 derangements that are corrected by available therapeutics, together with threshold values for 13 their administration. With this large prospective cohort study across five countries we have 14 developed data-driven algorithms for individualized hemostasis management of trauma 15 patients. We adopted a pragmatic approach focusing on available hemostatic therapies as an 16 addition to a baseline damage control resuscitation. The empiric ratio MTP continues until 17 hemostasis, adding the available hemostatic therapies as guided by TEG/ROTEM or CCT as 18 soon as the test results are available. In studying ROTEM and TEG devices in parallel we 19 have produced algorithms applicable to all centers regardless of which device is available. 20
This study therefore fills a considerable evidence gap in the role of viscoelastic hemostatic 21 assays in the management of bleeding trauma patients [16] [17] [18] 20, 21] . 22
23
The parameters proposed in this study will need further validation in subsequent studies. For 24 internal validation, the ACIT study continues to run across the INTRN sites. External 25 validation will be needed from other centers and networks, especially those in other countries 1 and healthcare systems. Although the parameters and thresholds used in our algorithms were 2 data driven, there was limited evidence for the choice or dose of therapeutic agents. We used 3 a combination of available evidence, guidelines and intrinsic expertise alongside the desire for 4 the algorithms to be broadly applicable at an international level. Each individual agent and 5
dose is worthy of further study. As a whole, the algorithms are being taken forward by the 6 TACTIC partners into a randomized controlled trial (RCT) of viscoelastic assays versus 7 conventional coagulation therapy (the iTACTIC trial, ClinicalTrials.gov Identifier: 8 NCT02593877). This should provide evidence for the whole algorithm approach, which can 9 be refined and updated with future investigations. 10
11
There are several limitations to our study in addition to the lack of a separate validation set. 12
Despite the large cohorts and high injury severity scores, the number of coagulopathic and 13 massively bleeding patients was around 15%. Some specific derangements, such as low 14 platelet counts, were very rare, especially as we focused on the first sample drawn after 15 admission. This will lead to bias to the negative predictive value of a parameter and 16 potentially under-represent their positive predictive value and overall accuracy. Thresholds 17 for hyperfibrinolysis had to be determined from clinical correlates in the absence of a 18 definitive laboratory comparator test. The prehospital use of tranexamic acid will have 19 contributed to the relatively low observed rates of admission hyperfibrinolysis, but should not 20 have affected the actual threshold levels we calculated. Further external validation studies 21 should be performed to confirm the applicability of these criteria for antifibrinolytic 22 administration. 23
Some of the differences in performance between ROTEM and TEG parameters are also likely 24 to be due to the difference in sample sizes between the two cohorts. As we aimed to develop 25 internationally relevant algorithms, we did not explore between-center variations in 1 prehospital or in-hospital practices. However, overall the clinical and transfusion practices at 2 the centers are more similar than they are different, and all adhere to modern practices of 3 damage control resuscitation [30] . We therefore believe the study findings represent the real-4 world situation and are thus broadly applicable across similar healthcare systems. 5 6 CONCLUSION 7
In this large prospective cohort study, we have determined the clinically optimal tests, 8 parameters and thresholds to guide hemostatic therapies in trauma patients. We present 9 algorithms for a precision approach to TIC, augmenting standard damage control resuscitation 10 practice. These algorithms are being taken forward for evaluation in the iTACTIC 11 multicenter randomized controlled trial of viscoelastic assays versus CCTs on clinical 12 outcomes in trauma hemorrhage. Table 1 : Baseline demographics, injury characteristics, admission parameters, transfusion 2 requirement and outcomes 3 Table 2 : Detection of Hypofibrinogenemia (Fibrinogen < 2.0 g/L) 4 Table 3 : Detection of Thrombocytopenia (platelet count < 100 x 10 9 /L) 5 
